
    
      During the treatment period, safety monitoring continued as initially foreseen. Reporting of
      post-study adverse events (AEs) and serious AEs (SAEs) continued as per protocol. In the best
      interest of the patient, no more biological samples for protocol research purposes (i.e.
      serum sampling for humoral immunity, whole blood sampling for pharmacogenetics) were taken.
    
  